{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-015494","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2024-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.785307+00:00","generated_at":"2026-06-03T13:50:34.197572+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Propanc Biopharma issues $27,500 convertible note to GS Capital Partners","bullets":["Entered into securities purchase agreement; note principal $27,500 at $25,000 purchase price (original issue discount).","Note bears 8% interest (24% on default), matures October 12, 2024; conversion price initially $0.0017/share.","Conversion price adjusts to $0.001 if stock trades below $0.0014 for 5 consecutive days; default triggers alternate fixed price.","Company may prepay at 110-125% within 180 days; after 180 days no prepayment right.","Note issued under Regulation D private placement; proceeds for general working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-015494","json":"https://secwatch.observer/filing/0001493152-24-015494.json","markdown":"https://secwatch.observer/filing/0001493152-24-015494.md","text":"https://secwatch.observer/filing/0001493152-24-015494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000149315224015494/0001493152-24-015494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000149315224015494/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T13:50:34.197572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3554eb215bd751b213f3e7eba6695542f294151c","claim":"Propanc Biopharma, Inc. incurred convertible notes of $27,500 with an investor at eight percent (8%) per annum maturing October 12, 2024.","evidence_excerpt":"Effective April 16, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $27,500 (the “Note”), for a purchase price of $25,000.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315224015494/0001493152-24-015494-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$27,500"},{"label":"Counterparty","value":"an investor"},{"label":"Rate","value":"eight percent (8%) per annum"},{"label":"Maturity","value":"October 12, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"c335bf23594a5411e314d61f756ad7d51891f6c9","claim":"Propanc Biopharma, Inc. entered into Purchase Agreement with an investor (the “Investor”) valued at aggregate principal amount of $27,500 (effective 2024-04-16).","evidence_excerpt":"Effective April 16, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $27,500 (the “Note”), for a purchase price of $25,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315224015494/0001493152-24-015494-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an investor (the “Investor”)"},{"label":"Value","value":"aggregate principal amount of $27,500"},{"label":"Effective","value":"2024-04-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}